beta-3 adrenergic receptor Agonists
4 drugsAbout beta-3 adrenergic receptor
The beta-3 adrenergic receptor (ADRB3) is a G protein-coupled receptor involved in detrusor muscle relaxation. Activation of ADRB3 leads to bladder relaxation. It has relevance in pharmaceutical interventions.
Human genetic studies provide moderate support for ADRB3 as a therapeutic target, with variants linked to peripheral vascular disease (score 0.49) and obesity (score 0.37). Gain-of-function variants appear protective against obesity.
ADRB3 is targeted by 3 FDA-approved small molecule drugs, including MIRABEGRON (MYRBETRIQ). These drugs are marketed by Ascent and APGDI for other therapeutic areas.
beta-3 adrenergic receptor Genetic Evidence Moderate
Genetic evidence offers moderate support for ADRB3, with a max score of 0.49.
Further investigation of ADRB3's role in peripheral vascular disease may reveal novel therapeutic opportunities.
💡 Why activation?
- • Gain-of-function variants reduce disease risk — enhancing activity may help
- • 100% directional consistency across 1 traits
- • Strong signal in nutritional or metabolic disease, phenotype pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
2 totalGWAS and other genetic studies link ADRB3 to 2 diseases.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top beta-3 adrenergic receptor Drugs
The competitive landscape is relatively concentrated, with only 2 companies holding approved drugs.
The limited number of players suggests a potential opportunity for new entrants in the ADRB3 market.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| MYRBETRIQ GRANULES | APGDI | 2021 | 2 |
beta-3 adrenergic receptor Drug Modality Landscape
Modalities
Routes of Administration
beta-3 adrenergic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
beta-3 adrenergic receptor Clinical Trials 113 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on beta-3 adrenergic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 29 | 27 | 1 | 1 | 96% |
| Phase 2 | 23 | 12 | 2 | 9 | 86% |
| Phase 3 | 26 | 17 | 2 | 7 | 89% |
| Phase 4 | 35 | 21 | 2 | 12 | 91% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved beta-3 adrenergic receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting beta-3 adrenergic receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
beta-3 adrenergic receptor Drug Approval Timeline (2012 - 2021)
The approval timeline spans 10 years, with the first drug approved in 2012 and the most recent in 2021.
The recent approval suggests continued interest in ADRB3, but market saturation should be considered.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 56 (10 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on beta-3 adrenergic receptor. A trial counts if an approved drug acting on beta-3 adrenergic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.